Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology
Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder cancer.
Fidia Announces Presentation of New Data on a Cartilage Explant Model at Orthopaedic Research Society (ORS) Annual Meeting
Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis
Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA) based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces new data will be presented at the Annual Meeting of the Orthopaedic Research Society (ORS) in New Orleans, LA, March 10th-13th,…
HYMOVIS®: An Innovation In Ha-Based Viscoelastic Hydrogel Technology In The Treatment Of Osteoarthritis Knee Pain
PARSIPPANY, NJ, May 8, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) - based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May